JP2024519335A5 - - Google Patents

Info

Publication number
JP2024519335A5
JP2024519335A5 JP2023569939A JP2023569939A JP2024519335A5 JP 2024519335 A5 JP2024519335 A5 JP 2024519335A5 JP 2023569939 A JP2023569939 A JP 2023569939A JP 2023569939 A JP2023569939 A JP 2023569939A JP 2024519335 A5 JP2024519335 A5 JP 2024519335A5
Authority
JP
Japan
Prior art keywords
administered
dose
pharmaceutical composition
fludarabine
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023569939A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024519335A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/028839 external-priority patent/WO2022241036A1/en
Publication of JP2024519335A publication Critical patent/JP2024519335A/ja
Publication of JP2024519335A5 publication Critical patent/JP2024519335A5/ja
Pending legal-status Critical Current

Links

JP2023569939A 2021-05-13 2022-05-11 がん免疫療法のための投薬レジメン Pending JP2024519335A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163201792P 2021-05-13 2021-05-13
US63/201,792 2021-05-13
US202263269316P 2022-03-14 2022-03-14
US63/269,316 2022-03-14
PCT/US2022/028839 WO2022241036A1 (en) 2021-05-13 2022-05-11 Dosing regimens for cancer immunotherapy

Publications (2)

Publication Number Publication Date
JP2024519335A JP2024519335A (ja) 2024-05-10
JP2024519335A5 true JP2024519335A5 (cg-RX-API-DMAC7.html) 2025-05-19

Family

ID=84029831

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023569939A Pending JP2024519335A (ja) 2021-05-13 2022-05-11 がん免疫療法のための投薬レジメン

Country Status (7)

Country Link
US (1) US20250073266A1 (cg-RX-API-DMAC7.html)
EP (1) EP4337228A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024519335A (cg-RX-API-DMAC7.html)
KR (1) KR20240032732A (cg-RX-API-DMAC7.html)
AU (1) AU2022272973A1 (cg-RX-API-DMAC7.html)
CA (1) CA3218640A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022241036A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210137085A (ko) 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
DE102022132084B4 (de) 2022-12-02 2024-08-22 Horia Hulubei National Institute for R & D in Physics and Nuclear Engineering (IFIN-HH) Vorrichtung zum Porieren und zum Beladen von Zellen sowie Verfahren hierfür
DE102022132082B4 (de) 2022-12-02 2024-08-08 Horia Hulubei National Institute for R & D in Physics and Nuclear Engineering (IFIN-HH) Verfahren zur Herstellung von genetisch transfizierten und mit Nanopartikeln und/oder einem zytotoxischen Stoff beladenen immunokompetenten Zellen sowie immunokompetente Zellen und medizinische Zusammensetzung.
DE102022132083B4 (de) 2022-12-02 2024-08-22 Horia Hulubei National Institute for R & D in Physics and Nuclear Engineering (IFIN-HH) Vorrichtung zum Porieren und zum Beladen von Zellen sowie Verfahren hierfür
EP4735011A1 (en) * 2023-06-27 2026-05-06 Nkarta, Inc. Dosing regimens for treatment of cancer
CN117430721B (zh) * 2023-10-25 2024-06-25 北京景达生物科技有限公司 Cd123靶向car-nk细胞的制备及其应用
WO2025106552A1 (en) * 2023-11-14 2025-05-22 Nkarta, Inc. Methods and compositions for treatment of leukemia

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011276590A1 (en) * 2010-06-28 2013-01-31 Threshold Pharmaceuticals, Inc. Treatment of blood cancer
WO2014066137A1 (en) * 2012-10-22 2014-05-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions and methods for enhancing cancer immunotherapy
EP3077004B1 (en) * 2013-12-05 2020-02-19 F.Hoffmann-La Roche Ag Novel combination treatment for acute myeloid leukemia (aml)
CN117363636A (zh) * 2017-03-27 2024-01-09 新加坡国立大学 一种编码嵌合受体的多核苷酸
ES3068417T3 (en) * 2018-09-13 2026-05-29 Nkarta Inc Natural killer cell compositions and immunotherapy methods for treating a liver tumor
KR20210137085A (ko) * 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
WO2021035054A1 (en) * 2019-08-20 2021-02-25 Precision Biosciences, Inc. Lymphodepletion dosing regimens for cellular immunotherapies

Similar Documents

Publication Publication Date Title
JP2023518049A5 (cg-RX-API-DMAC7.html)
IL273201B1 (en) Novel platforms for co-stimulation, novel car designs and other enhancements for adoptive cellular therapy
JP7857980B2 (ja) Cd19指向性キメラ抗原受容体および免疫療法におけるその使用
JP2021500861A5 (cg-RX-API-DMAC7.html)
JP2021525509A5 (cg-RX-API-DMAC7.html)
JP2024518011A5 (cg-RX-API-DMAC7.html)
US20200038443A1 (en) Multi-function and multi-targeting car system and methods for use thereof
US11918634B2 (en) Method for activating T cells for cancer treatment
WO2020247392A1 (en) Combinations of engineered natural killer cells and engineered t cells for immunotherapy
US20230028399A1 (en) Bcma-directed cellular immunotherapy compositions and methods
JP2022545167A5 (cg-RX-API-DMAC7.html)
JP2020517263A5 (cg-RX-API-DMAC7.html)
US20250073266A1 (en) Dosing regimens for cancer immunotherapy
EP3612222A1 (en) Compositions and methods for treating cancer
US20250319185A1 (en) Bcma-directed cellular immunotherapy compositions and methods
IL297514A (en) Vectors and methods for in vivo transduction
JP2023525720A5 (cg-RX-API-DMAC7.html)
JP2024510900A5 (cg-RX-API-DMAC7.html)
US20230398216A1 (en) Chimeric activation receptors
WO2022222845A1 (zh) 混合的固有淋巴细胞、制备方法及其应用
WO2023207390A1 (zh) 一种ciita基因被敲除的工程化免疫细胞及其用途
JP2022516710A5 (cg-RX-API-DMAC7.html)
JP2025524564A (ja) Cd19指向性がん免疫療法の投与レジメン
US20210079111A1 (en) Cd19-cd20 bispecific and dual passway car-t and methods for use thereof
JP2019531742A5 (cg-RX-API-DMAC7.html)